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“cold” ischemia for organs harvested from cadaver do-
nors eventuate from complexities of obtaining permis-
sion to use the organs, coordinating harvest of multiple
organs, preserving organs for transportation, identifying
appropriate recipients, and performing unscheduled
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Reperfusion of blood through ischemic tissue resultsEmory University
Atlanta, Georgia 30322 in a set of reactions that can cause injury to vascular
and parenchymal cells. Pathologically, these are charac-‡The Department of Immunology and
The Urological Institute terized by deposition of complement, upregulation of
adhesion molecules, inflammatory cell infiltration, andCleveland Clinic Foundation
Cleveland, Ohio 44195 cytokine release (Weisman et al., 1990; Halloran et al.,
1992; Weiser et al., 1996). Activation of complement,
platelets, neutrophils, and macrophages following is-
chemia extends the initial damage.
Over the past several decades, advances in the study
Ischemic injury can be compounded by the traumatic
of T cell biology have led to numerous experimental
injury and emergency interventions that precede organ
protocols and strategies to induce transplantation toler-
harvest from cadaver donors (Wilhelm et al., 2000). In
ance or to dramatically inhibit rejection responses. Un-
addition, recipients also are subjected to therapeutic
fortunately, in general these approaches have met with
treatments before and during transplantation that may
considerably less success in the clinical setting. While
amplify innate immune responses. Examples include the
differences in the immune systems of inbred laboratory
use of dialysis or ventricular assist devices prior to trans-
rodents and heterogeneous human populations un-
plantation and cardiopulmonary bypass intraoperatively
doubtedly account for many of these discrepancies, rel-
(Van Loo et al., 1998; Fitch et al., 1999).
atively little attention has been given to potentially im-
This is not to suggest that a concomitant innate re-
portant differences between experimental transplant
sponse to the acute injury associated with the transplant
models and the practice of clinical transplantation. In
procedure is required to elicit allograft rejection. Studies
most transplant experiments, organs and tissues are
using T cell–deficient mice have shown that prompt re-
removed from unmanipulated healthy donors under
jection can occur after T cell reconstitution even when
ideal surgical conditions and immediately transplanted
skin or cardiac allografts have been allowed to recover
into healthy recipients. This simulates most closely the
and heal for more than 100 days (Bingaman et al., 2000).
clinical conditions of a renal transplant performed from
Rather, concomitant stimulation of the innate immune
a living donor. However, most organs are harvested from
system leads to heightened expression of MHC mole-
cadaver donors. Unlike the carefully screened and con-
cules, costimulatory molecules, cytokines, and other
trolled living donor, cadaveric organs are harvested
factors that may alter the threshold for T cell activation,
under conditions of extreme physiologic stress (summa-
influence the cytokine profile of the adaptive immune
rized in Table 1), many of which can stimulate compo-
response, promote the more rapid recruitment of allo-
nents of the innate immune system.
reactive T cells, or directly promote injury of the trans-
In this review, we highlight selected aspects of the
planted organ. For example, recent evidence suggests
innate immune system, in particular the complement
that ischemia reperfusion injury alone in the absence of
cascade and natural killer (NK) cells, and the mecha-
an alloantigenic stimulus results in a histological and
nisms by which they may have a significant impact on
functional picture that is very similar to chronic trans-
the alloimmune responses to organ transplants.
plant nephropathy. This process is associated with
Heightened interest in the potential impact of innate
upregulation of B7 costimluatory and MHC class II mole-
immune responses on subsequent alloimmune re-
cules and is inhibited by administration of CTLA4-Ig
sponses has emerged as the result of the recent use of
(Chandraker et al., 1997; Takada et al., 1997).
renal transplants from living genetically unrelated do-
This review will focus on the mechanisms by which
nors. These transplants from histoincompatible living
two of the best-defined mediators of innate immunity,
unrelated donors survive as well or better than trans-
complement and natural killer cells, influence the adap-
plants from “well-matched” cadaver donors (D’Alessan-
tive immune response and promote transplant injury.
dro et al., 1998). This disparity in survival is magnified
when the renal transplant does not function immedi-
Complementately.
Activation of complement is an essential feature of theSome of the major differences between organs har-
inflammatory response generated by ischemia-reperfu-vested from cadaver and living donors are related to
sion, dialysis, and cardiopulmonary bypass (Weismanischemia-reperfusion. Longer periods of “warm” and
et al., 1990; Halloran et al., 1992; Weiser et al., 1996;
Van Loo et al., 1998; Fitch et al., 1999). Complement
activation is integral to the tissue injury resulting from§ To whom correspondence should be addressed (e-mail: wbaldwin@
jhmi.edu). these interventions because interrupting the comple-
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Trauma, surgery, or infection can stimulate an acuteTable 1. Stresses Incurred by Transplanted Organs in Donor and
synthesis of these proteins by the liver that results inRecipient that Can Alter Innate Immune Responses
as much as a 1,000-fold increase in plasma concen-Donor Transport Recipient
tration of CRP within hours to days. This response is
Mortal injury regulated by proinflammatory mediators, predominantly
(MVA, GSW, CVA)a IL-6, and is largely uninhibited by anti-inflammatory
Emergency interventions
drugs. Consequently, circulating CRP would be expectedBrain death
to be elevated in cadaver donors and transplant recipi-Postmortum support
ents. Studies have confirmed that CRP is elevated forOrgan harvest
Cold ischemia several days after renal or cardiac transplantation (Harris
Warm ischemia et al., 1996; Wolbink et al., 1996).
(Cardiac by-pass) CRP is composed of five identical 206 amino acid
Drug therapy
subunits arranged in a planar ring structure. The pen-Infection
tameric structure and the capacity to activate comple-Alloimmunity
ment are features CRP shares with other members of
a MVA, motor vehicle accident; GSW, gunshot wound; CVA, cerebral the pentraxin family of proteins including serum amyloid
vascular accident.
P component, another prototypical acute-phase pro-
tein, and the long pentraxin TSG-14/PTX3 that is pro-
duced by monocytes and endothelial cells (Rovere etment cascade by exogenous inhibitors or genetic defi-
al., 2000).ciencies decreases the inflammatory cell infiltrates and
CRP was discovered and named because of its reac-tissue injury (Weisman et al., 1990; Weiser et al., 1996;
tivity to pneumococcal C-polysaccharide, but CRP alsoFitch et al., 1999).
binds to phosphatidylcholine and sphingomyelin thatAlthough there is general agreement that complement
are exposed on plasma membranes of injured cells andcan contribute to ischemia-reperfusion injury, the mech-
to chromatin that is exposed on apoptotic or necroticanism of complement activation in this setting has not
cells. CRP can bind to other ligands exposed duringbeen clarified fully. The complement cascade can be
tissue injury, including laminin and fibronectin, the prin-activated through three different initial pathways: the
cipal adhesive molecules in basal lamina and in connec-classical (C1, C4, and C2), alternative (factor B), and
tive tissue, respectively.mannose binding lectin (MBL) pathways (Figure 1). The
After CRP complexes with a tissue ligand through itsmajority of evidence indicates that ischemia-reperfusion
five calcium-dependent binding sites on one surface, itleads to complement activation through the classical or
can activate complement or Fc receptor bearing cellsMBL pathway.
(Figure 2). CRP activates the classical pathway of com-Antibodies are the most thoroughly investigated
plement by binding to the collagen-like region of C1q.mechanism of activating the classical pathway of com-
CRP also interacts with the high- and low-affinity recep-plement. Clinically, “natural” antibodies to the major
tors for IgG, FcgRI and FcgRII, respectively. These inter-
blood group antigens and alloantibodies induced by
actions can lead to enhanced antigen presentation and
previous transfusions, pregnancies, or transplants are
production of IL-1 and TNF.
known to activate complement. The degree of tissue
CRP has been implicated in the pathogenesis of isch-
injury caused by these antibodies depends on the iso- emic injury in vivo by its colocalization with complement
type, affinity, and titer of the antibodies as well as the in atherosclerotic lesions and acute myocardial infarcts.
expression of the target antigen. Weiser and coworkers Griselli and colleagues (Griselli et al., 1999) have ex-
(Weiser et al., 1996) have raised the possibility that natu- ploited their finding that rat CRP does not activate com-
ral antibodies to normally cryptic antigens may contrib- plement to develop an in vivo model, in which human
ute to complement-mediated ischemia-reperfusion in- CRP binds to damaged cells and activates rat comple-
jury. They demonstrated that vascular leakage following ment. In this model, an injection of human CRP into rats
ischemia-reperfusion of skeletal muscle was associated was found to increase the area of ischemia and infarct
with the deposition of IgM and complement. Tissue in- caused by a temporary ligation of a coronary artery.
jury was decreased in both immunoglobulin and com- Both CRP and complement were deposited in the tissue
plement (C4 or C3) knockout mice. Furthermore, recon- at risk.
stitution of immunoglobulin knockout mice with serum The potential for CRP to activate complement shortly
from normal mice restored susceptibility to ischemia- after transplantation is supported by measurements of
reperfusion injury. To date, the potential target of these circulating complexes of CRP and complement compo-
natural IgM antibodies has not been defined, but natural nents. These complexes increase significantly within the
polyreactive autoantibodies are an important compo- first 3 days after clinical renal transplantation (Wolbink
nent of the normal B cell repertoire. Some natural polyre- et al., 1996).
active IgM autoantibodies have been defined that recog- Similar to CRP, MBL is a component of the innate
nize epitopes on apoptotic cells (Shaw et al., 2000). immune response to pathogens. MBL, like C1q, is a
These would be good candidates for complement acti- collectin composed of subunits with collagen-like tails
vation in ischemically injured tissues. attached to globular lectin heads. The complete MBL is
Besides antibodies, several acute phase proteins can formed by multimers of 2–6 subunits. Each head con-
bind C1q of the classical pathway of complement. tains three C-type lectin domains that bind to terminal
C-reactive protein (CRP) is the major acute-phase pro- mannose, fucose, or glucosamine in oligosaccharides
on pathogens. After binding, MBL can cleave C2 andtein in humans (for recent review see Du Clos, 2000).
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oxidative stress in vitro and in rat hearts after temporary
ligation of a coronary artery (Collard et al., 2000). In this
study, activation of complement was inhibited by free
D-mannose or monoclonal antibodies to MBL. Like CRP,
MBL is capable not only of activating the classical com-
plement components C4 and C2 but also of serving as
a ligand for receptors on macrophages (Bajtay et al.,
2000).
C3 as hub of complement cascade: C3 is the hub of
the complement cascade quantitatively and function-
ally. All three pathways of complement activation con-
verge in the activation of C3.
C3 is present in plasma at high concentrations (1.3
mg/ml). Additional C3 can be produced in tissues by
infiltrating macrophages (Bajtay et al., 2000) and certain
parenchymal cells within a transplanted organ, including
vascular endothelial cells, glomerular mesangial cells,
renal tubular epithelial cells, and alveolar epithelial cells
(Brooimans et al., 1991; Takada et al., 1997; Pratt et al.,
2000). Within inflammatory foci, the production of C3
by different parenchymal cells may be augmented by
proinflammatory cytokines, such as IL-1, IL-2, IL-6, and
TNFa (Brooimans et al., 1991). Macrophage production
of C3 is also increased in the presence of C1q through
the C1q receptor (Bajtay et al., 2000).
Activation of C3 is accomplished by enzymatic cleav-
age into two biologically active fragments: a small solu-
ble mediator of chemotaxis and activation (C3a) and a
large fragment that can bind covalently to proteins or
carbohydrates (C3b). Once bound, C3b is subject to two
competing processes: (1) an amplification loop through
Figure 1. The Complement Cascade Can Be Activated through factor B of the alternative pathway that can augment
Three Different Initial Pathways: The Classical (C1, C4, and C2), the deposition of C3b and (2) regulation.
Alternative (Factor B), and Mannose Binding Lectin (MBL) Pathways
Regulation of C3 is controlled by a group of regulators
All three pathways converge in the activation of C3. Activation of of complement activation (RCA). The RCA gene cluster
C3 and C5 occurs by enzymatic cleavage into two biologically active
codes for six inhibitors of C3 activation: membrane co-fragments. The small fragments (C3a and C5a) mediate chemotaxis
factor protein (MCP, CD46), complement receptor 1and activation through separate receptors (C3aR and C5aR) on leu-
(CR1, CD35) and complement receptor 2 (CR2, CD21),kocytes. Activation of monocytes through their C5a receptor causes
production of proinflammatory cytokines, such as IL-1, IL-6, IL-8, decay accelerating factor (DAF), C4 binding protein
and TNFa. The large fragment of C3 can bind covalently to proteins (C4bp), and factor H. The first four regulators are ex-
or carbohydrates. Deposition of C3b can be increased through an pressed as membrane bound proteins, while the last
amplification loop with factor B of the alternative pathway. The two circulate in the plasma. MCP and DAF are present on
terminal components of complement (C5b-C9) form a tubular struc-
a wide variety of cells, including leukocytes and vascularture, the membrane attack complex (MAC).
endothelial cells, while CR1 and CR2 are expressed on
selected leukocytes and antigen-presenting cells.
C4 through two associated serine proteases (MASP-1 When C3b is bound by CR1 or factor H, it can be
and -2) that are similar to C1r and C1s. cleaved successively by factor I, leaving first iC3b and
In vitro and in vivo studies suggest that MBL might then C3dg attached to the membrane (Figure 3). C3b,
also activate complement following ischemia-reperfu- iC3b, and C3dg serve as ligands for cells with comple-
sion. MBL has been shown to colocalize with comple- ment receptors CR1, CR3 and CR2, respectively. Macro-
phages, which possess CR1 and CR3, are characteristicment deposition on human vascular endothelium after
Figure 2. CRP Is Composed of Five Identical
Subunits Arranged in a Planar Ring Structure
CRP binds to phosphatidylcholine and sphin-
gomyelin that are exposed on plasma mem-
branes of injured cells. After CRP complexes
with a tissue ligand on one surface, it can
activate the classical pathway of complement
by binding to the collagen-like region of C1q.
CRP binds factor H in addition to C1q and
thereby truncates complement activation at
C3. CRP also interacts with the high- and low-
affinity receptors for IgG, FcgRI, and FcgRII,
respectively.
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Figure 3. C3 Is Activated by Enzymatic Cleavage into C3a and C3b that Can Bind Covalently to Proteins or Carbohydrates through a Thioester
Bond
C3b is cleaved successively by factor I leaving first iC3b and then C3dg bound to the membrane. CR1 or factor H serve as cofactors to Factor
I. C3b, iC3b, and C3d stimulate cells with complement receptors CR1, CR3, and CR2, respectively.
features of ischemia-reperfusion damage in transplants activate endothelial cells directly through a C5a receptor
(Foreman et al., 1994). Activation of endothelial cells by(Baldwin et al., 1999).
Factor H is particularly relevant to activation of com- C5a can be augmented in the presence of TNFa. The
activities of C5a are important early steps in initiatingplement by CRP. CRP binds factor H in addition to C1q,
and thereby effectively truncates complement activation macrophage activation and possibly T cell recruitment
(Nataf et al., 1999; Tsuji et al., 2000).at C3 (Du Clos, 2000). This leads to the deposition of
the ligands for CR1, CR3, and CR2 without generating In the clinical setting, a recombinant antibody to C5
has been found to inhibit leukocyte activation as mea-the inflammatory C5a or terminal complement compo-
nents (Figure 2). sured by CR3 expression in patients undergoing surgery
requiring cardiopulmonary bypass (Fitch et al., 1999).C3a and C5a as chemoattractants and activators: ac-
tivation of C5 as well as C3 is accomplished by enzy- The bioincompatible materials in cardiopulmonary by-
pass pumps and dialysis machines are known to upreg-matic cleavage into two biologically active fragments.
The small fragments (C3a and C5a) mediate chemotaxis ulate multiple aspects of the innate immune system,
which can affect subsequent transplant function (Vanand activation through separate receptors (C3aR and
C5aR) on leukocytes. C5a is quantitatively much more Loo et al., 1998).
Membrane attack complex (MAC) as an activator ofpotent as a chemotatic agent than C3a and affects a
wider range of cells, including neutrophils, monocytes, leukocytes and vascular cells: the terminal components
of complement (C5b-C9) form a tubular structure, thebasophils, and eosinophils. C3a acts primarily on mast
cells and eosinophils (DiScipio et al., 1999). membrane attack complex. If only low densities of MAC
are assembled on cells, complement regulatory pro-Activation of monocytes through their C5a receptor
causes production of proinflammatory cytokines, such teins, such as CD59, inhibit lysis (Lachmann, 1991).
However, insertion of sublytic quantities of MAC intoas IL-1, IL-6, IL-8, and TNFa, and upregulation of CR1
and CR3 (Arnaout et al., 1984; Ember et al., 1994). The endothelial cells in vitro causes the translocatation of
P-selectin and von Willebrand factor from Weibel-Paladeincreased synthesis of proinflammatory cytokines can
act together with C5a to promote hepatic synthesis of storage granules to the plasma membrane (Hattori et
al., 1989). Similarly, MAC stimulates the translocationCRP (Szalai et al., 2000). C5a has also been reported to
Review
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of P-selectin from platelet a-granules to the plasma clearly effector cells mediating rejection of allogeneic
lymphoid cells and bone marrow grafts (Manilay andmembrane and the secretion of mediators from storage
Sykes, 1998), the role of these cells during the rejectiongranules (Sims and Wiedmer, 1991). P-selectin initiates
of solid tissue allografts remains unclear.adhesion of monocytes and platelets to the endothelium
In response to tumors and virus-infected cells, NKand costimulates their production of inflammatory medi-
cells express many different effector functions followingators (Celi et al., 1994; Weyrich et al., 1996). Intravascular
cellular activation (Biron et al., 1999). A critical functionaggregation of P-selectin and von Willebrand factor ex-
of NK cells in these responses is perforin/granzymepressing platelets is a prominent feature of experimental
B–mediated cytolysis of the target cells. In addition,models of antibody-mediated rejection that is de-
activated NK cells produce IFNg, TNFb, TNFa, and sev-creased in the absence of MAC deposition (Qian et al.,
eral other proinflammatory cytokines. These activities1999).
are expressed by alloantigen-primed T cells during re-In addition to releasing preformed mediators, MAC
jection of solid tissue allografts. The absence of self-activated endothelial cells synthesize IL-8, monocyte
class I MHC molecules on allogeneic cells would bechemotactic protein 1 (MCP-1), P-selectin, tissue factor,
expected to activate NK cells to express these functionsplatelet derived growth factor (PDGF), and basic fibro-
early following solid organ transplantation. Activation ofblast growth factor (bFGF) (Benzaquen et al., 1994; Kil-
NK cells to mediate direct cytolysis of allogeneic targetgore et al., 1996; Tedesco et al., 1997). MCP-1 would
cells could indicate the ability of NK cells to directlyincrease the macrophage recruitment to the transplant.
mediate rejection of solid tissue allografts. Alternatively,Macrophages are a conspicuous component of the infil-
NK cell activity may augment inflammation and facilitatetrates that characterize reperfusion injury of transplants
the rejection process mediated by alloantigen-specific(Takada et al., 1997; Baldwin et al., 1999).
T cells following priming.Complement in transplants: we have reported that
NK cell infiltration of renal and cardiac allografts hasischemic changes in endomyocardial biopsies are asso-
been observed shortly after transplantation in both clini-ciated with complement deposition in biopsies obtained
cal and experimental models (Nemlander et al., 1983;1–3 weeks after cardiac transplantation (Baldwin et al.,
Heidecke et al., 1985; Blancho et al., 1992; Petersson1999). Diffuse capillary and pericapillary deposition of
et al., 1997). This infiltration often occurs before evi-C4d or C3d were detected in over one-third of the endo-
dence of T cell infiltration and is consistent with the rolemyocardial biopsies, the majority of which had histologi-
of NK cells as early innate effector cells in response tocal evidence of ischemic injury. Although only a minority
antigenic inflammation. Furthermore, NK cells in renalof the biopsies had evidence of rejection within 3 weeks
allografts have been observed to express granzymes Aafter transplantation, C4d and C3d deposition did corre-
and B during acute rejection episodes (Kummer et al.,late with repeated acute rejection episodes on subse-
1995). Petersson and coworkers (Petersson et al., 1997)quent biopsies.
have reported that rat NK cell-mediated cytolysis ofOur longitudinal studies demonstrated that these
donor target cells in vitro is increased in NK cell popula-markers of complement activation could be detected as
tions isolated from recipients of allogeneic heart grafts.long as 3 weeks after transplantation. This may reflect
These results indicate that NK cells are not only presenteither the retention of the covalently bound C4d and
but are activated to effector function following infiltra-C3d on the surface of injured tissue or the continued
tion of solid organ allografts.local activation of complement in the damaged tissue
Although NK cell activation is evident during acutebecause the ischemic injury and macrophage infiltrates
rejection of solid tissue allografts, the ability of NK cellswere not completely resolved at these longer intervals
to directly mediate rejection of the grafts is unlikely. Itin some biopsies. In a rat model of cardiac transplanta-
has long been recognized that skin and heart allograftstion, we have demonstrated that macrophages in the
are not rejected following transplantation to nude, RAG-
graft infiltrates can be a significant source of comple-
1/22/2, or SCID mouse recipients that have high levels
ment production (Qian et al., 1999).
of NK cell activity. Studies from several laboratories
have also indicated the inability of NK cells to mediate
NK Cells rejection of allogeneic skin or heart grafts in immuno-
Natural killer cells are an important component of im- competent recipients (Heidecke et al., 1985; Markus et
mune surveillance, playing a critical role in protective al., 1991). In contrast, NK cells are potent effector cells
responses to viruses and tumors (Biron et al., 1999). mediating the rejection of xenogeneic skin and heart
Unlike T and B lymphocyte responses, expression of allografts when hyperacute rejection is circumvented
NK cell function does not require prior sensitization. (Blakely et al., 1994; Gorulay et al., 1998). This suggests
NK cell activity is controlled by the balance of signals that NK cell inhibitory receptors that may be stimulated
received from receptors that activate versus inhibit the by allogeneic class I MHC molecules in some graft recip-
cells (Lanier, 1998). NK cells express members of two ients are not stimulated by xenogeneic class I MHC
superfamilies of class I MHC binding receptors. Both of molecules.
these families include receptors that either stimulate or Since NK cell activity does not require prior sensitiza-
inhibit NK cell activation. NK cells also express activat- tion, the allograft endothelium would appear to be an
ing receptors that are stimulated independently of class ideal target for the expression of NK cell effector func-
I MHC engagement (Moretta et al., 2000). NK cells are tion. Studies by Ayalon and coworkers (Ayalon et al.,
activated by low or absent self-class I MHC expression, 1998) have shown that among a panel of different cell
as predicted by the “missing self” hypothesis proposed types tested, endothelial cells were the most susceptible
to NK cell-mediated cytolysis. Furthermore, NK cell-by Ljunggren and Ka¨rre (1990). Although NK cells are
Immunity
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mediated cytolysis of endothelial cells is enhanced by likely that they have underestimated the importance of
innate immune responses that are involved in the recipi-the CX3C chemokine fractalkine (Yoneda et al., 2000).
Several CC chemokines including MCP-1 also enhance ent’s response to an allograft in clinical transplantation.
In the clinical setting, cadaveric organs are harvestedNK cell-mediated cytolysis of target cells (Taub et al.,
1995). Endothelial cell production of both fractalkine from donors who have suffered acute brain death, sub-
jected to variable periods of cold and warm ischemia,and MCP-1 is induced early following transplantation.
In addition to direct injury to the allograft endothelium, and transplanted into critically ill recipients, providing a
powerful stimulus to the innate immune system. TheseNK cell interaction may facilitate the rejection process
indirectly. Studies by several groups of investigators systemic and local factors could promote the activation
of the complement cascade via CRP, natural antibody,have indicated NK cell production of IFNg during interac-
tion with allogeneic endothelial cells (Watson et al., 1995; and MBL-dependent mechanisms. Complement activa-
tion promotes allograft injury directly via MAC and indi-Timonen, 1997; Ayalon et al., 1998). IFNg stimulates
class I and class II MHC expression on the endothelial rectly via the activating and chemoattractant effects of
C3a and C5a on macrophages, neutrophils, basophils,cell surface, rendering them more susceptible to attack
by alloantigen-specific T cells following priming and re- eosinophils, and endothelial cells. Interestingly, while
most acute rejection responses are characterized bycruitment to the graft site (McDouall et al., 1997). NK
cell activity also stimulates adhesion molecule expres- lymphocytic infiltrates, a subset contains large numbers
of eosinophils and/or basophils, which has been sug-sion and production of chemokines that direct the re-
cruitment of alloantigen-primed T cells and other recipi- gested to be a marker of poorer prognosis. Further in-
vestigation on the role of complement cleavage prod-ent leukocyte populations to the allograft. NK cell
activity amplifies the intraallograft production of several ucts and other factors that influence the composition
graft infiltrating cells may help define the mechanismsCXC and CC chemokines in murine skin allografts within
the first 3 days posttransplant (Kondo et al., 2000). This involved in these distinct forms of rejection and suggest
more specific and effective therapeutic approaches.production appears to be dependent on TNFa produc-
tion and not on NK cell-mediated cytolysis or production The role of the NK cell response in organ allograft
rejection also warrants further investigation. While ro-of IFNg. These studies indicate that NK cell activity may
increase inflammation in the graft and enhance alloanti- dent models indicate that NK cells are unlikely to be
sufficient to independently reject a nonhematopoieticgen-primed T cell recruitment to the graft site. Endothe-
lial cell expression of class II MHC is also induced allograft, it is likely that in some settings NK cell re-
sponses may influence or play an important role in thethrough IFNg and CIITA-independent mechanisms dur-
ing interaction with NK (Collinge et al., 1998). rejection response. NK cells have been observed to infil-
trate both cardiac and renal allografts and to produce orA final aspect of the interaction between NK cells
and the vascular endothelium of allografts shortly after promote the release of effector molecules (granzymes),
cytokines (IFNg), and chemokines that regulate thetransplantation warrants some consideration. NK cells
express receptors for at least two complement compo- adaptive immune response.
While it is clear that MHC matching influences clinicalnents, C1q and iC3b (Timonen et al., 1988; Lovik et al.,
2000). C3 deposition on target cells has been shown to renal allograft survival, relatively little is known about
the rules that govern NK cell recognition of allogeneicenhance NK cell-mediated lysis (Parker et al., 1995),
suggesting that the presence of complement compo- MHC molecules via their inhibitory and activatory recep-
tors. It is possible that certain MHC disparities may elicitnents at the endothelial surface of allografts may en-
hance NK cell activation and damage to the endothe- either greater or lesser activation of NK cells and that
this may in turn influence the degree to which NK cellslium. Binding to tumor cell expressed heat shock protein
Hsp70 also increases NK cell lytic function and IFNg participate in the rejection process in a given donor-
recipient pair.production (Multhoff et al., 1999). Following many types
of trauma, endothelial cells express Hsp70 (Zhu et al., This review has focused on the effects of innate immu-
nity on transplants in the perioperative period. This is1994), and this may present another mechanism stimu-
lating or enhancing recipient NK cell activation during the time when the transplanted organ is most vulnerable
and visible to innate and adaptive immune responseinteraction with the allograft endothelium. Collectively,
these results suggest that the innate immune molecular elements because of the physiological insults incurred
complexes that form in the vascular endothelium may from harvesting, transportation, and transplantation. It
either directly activate or augment the activation of NK should be emphasized that these early events have long-
cells. This activation could result in endothelial cell lysis term consequences. Renal transplants with delayed
or indirectly amplify allograft inflammation and facilitate graft function and acute rejections have a greater inci-
T cell recruitment to the graft and/or accelerate the re- dence of chronic dysfunction. These long-term con-
jection process through stimulation of allogeneic MHC sequences may be related to decreased functional
molecules on graft cells. reserves or increased antigen sensitization. Innate im-
munity can also be of consequence at later times after
transplantation, such as during infectious episodes.Summary
CMV infections, for example, frequently trigger coinci-Much of our knowledge of the biology of allograft rejec-
dent rejection episodes. In the future, multiple aspectstion has come from carefully designed reductionist ro-
of organ allograft injury (including some of the adaptivedent experimental systems. While these models have
immune responses to organ allografts) may be modifiedprovided powerful tools for dissecting the mechanisms
of the adaptive immune response to an allograft, it is by inhibiting selected components of innate immunity.
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